<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002096</url>
  </required_header>
  <id_info>
    <org_study_id>059E</org_study_id>
    <secondary_id>ICM 1776</secondary_id>
    <nct_id>NCT00002096</nct_id>
  </id_info>
  <brief_title>A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine</brief_title>
  <official_title>A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine whether there is a pharmacokinetic drug interaction between oral ganciclovir and&#xD;
      oral zidovudine (AZT) and between oral ganciclovir and oral didanosine (ddI). To determine&#xD;
      whether concurrent administration of probenecid affects the pharmacokinetics of oral&#xD;
      ganciclovir. To obtain data on the short-term safety of oral ganciclovir administered&#xD;
      concurrently with AZT, ddI, or probenecid in HIV-positive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients currently on either AZT or ddI receive ganciclovir therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Concomitant AZT or ddI.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Probenecid.&#xD;
&#xD;
          -  Aerosolized pentamidine.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Asymptomatic HIV infection.&#xD;
&#xD;
          -  CMV seropositivity or CMV culture positivity at present or at any time in the past.&#xD;
&#xD;
          -  No history of CMV disease (e.g., retinitis, colitis) or any other AIDS-defining&#xD;
             illness.&#xD;
&#xD;
          -  Treatment with AZT or ddI for at least 1 month prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Uncontrolled diarrhea (three or more loose stools/day).&#xD;
&#xD;
          -  Clinically significant gastrointestinal symptoms including persistent nausea or&#xD;
             abdominal pain.&#xD;
&#xD;
          -  AZT patients only:&#xD;
&#xD;
          -  Deficiency in glucose-6-phosphate dehydrogenase.&#xD;
&#xD;
          -  ddI patients only:&#xD;
&#xD;
          -  Grade 2 or worse peripheral neuropathy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Combination antiretroviral therapy.&#xD;
&#xD;
          -  G-CSF or GM-CSF.&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Amikacin.&#xD;
&#xD;
          -  Captopril.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
&#xD;
          -  Cimetidine.&#xD;
&#xD;
          -  Cyclosporine.&#xD;
&#xD;
          -  Glutethimide.&#xD;
&#xD;
          -  Gentamicin.&#xD;
&#xD;
          -  Griseofulvin.&#xD;
&#xD;
          -  Ibuprofen.&#xD;
&#xD;
          -  Imipenem-Cilastatin.&#xD;
&#xD;
          -  Lithium.&#xD;
&#xD;
          -  Methicillin.&#xD;
&#xD;
          -  Methotrexate.&#xD;
&#xD;
          -  Naproxen.&#xD;
&#xD;
          -  Pentamidine (Pentam 300) (Aerosolized drug permitted).&#xD;
&#xD;
          -  Phenacetin.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Piroxicam.&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Tobramycin.&#xD;
&#xD;
          -  Vidarabine.&#xD;
&#xD;
          -  Zalcitabine.&#xD;
&#xD;
          -  Other investigational drugs.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  History of hypersensitivity to acyclovir or ganciclovir.&#xD;
&#xD;
          -  AZT patients only:&#xD;
&#xD;
          -  History of gout, uric acid, kidney stones, peptic ulcer or porphyria.&#xD;
&#xD;
          -  ddI patients only:&#xD;
&#xD;
          -  History of pancreatitis or alcoholism, or seizures within 6 months prior to study&#xD;
             entry or prior need for anticonvulsant therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Combination antiretroviral therapy within 1 month prior to study entry.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  AZT at 500 mg/day for at least 1 month prior to study entry (with 100 mg administered&#xD;
             five times per day for at least 1 week prior to study entry). OR&#xD;
&#xD;
          -  ddI at recommended dose for at least 1 month prior to study entry (with 250 mg&#xD;
             administered every 12 hours for at least 1 week prior to study entry).&#xD;
&#xD;
        History of alcoholism (in ddI patients).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ctr for Special Immunology</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown Univ Med Ctr</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ TX Galveston Med Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaines K, Wong R, Jung D, Cimoch P, Lavelle J, Pollard R. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid. Int Conf AIDS. 1994 Aug 7-12;10(1):7 (abstract no 004B)</citation>
  </reference>
  <verification_date>November 1993</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Drug Interactions</keyword>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

